Safe use of ribociclib in a patient with HR+/HER2− metastatic breast cancer receiving chronic hemodialysis

İntroduction The standard treatment for hormone receptor-positive and HER2-negative metastatic breast cancer is a combination of CDK4/6 inhibitors and endocrine therapy. Case report In this case, our aim was to demonstrate the safety and effectiveness of ribociclib in a patient with metastatic breast cancer undergoing hemodialysis three days a week. Management & Outcome A 59-year-old female patient with end-stage kidney disease who undergoes hemodialysis was diagnosed with metastatic breast cancer. The tumour is hormone receptor positive and HER2 negative. She received ribociclib with a reduced dose due to haematological toxicity, as well as letrozole and denosumab due to bone metastasis. PET/CT scans revealed that the primary tumour had regressed by 50%, with partial regression of the metabolic activity of the bone metastases. Ribociclib was administered safely and effectively for nine months. Discussion We presented our experience of using ribociclib in a patient with metastatic breast cancer who was receiving hemodialysis. Ribociclib was administered safely, and a response to the treatment was achieved.